Yue et al. showed that Idelalisib inhibited AKT, activated FoxO3a, and further upregulated Bim, thus promoting the development of mitochondria-dependent apoptosis in HCC cells [61]. This evidence concerns the gene AKT1 and hepatocellular carcinoma.